Biodexa Pharmaceuticals (BDRX) Competitors $7.13 +0.33 (+4.85%) Closing price 08/8/2025 03:59 PM EasternExtended Trading$7.10 -0.03 (-0.42%) As of 08/8/2025 07:53 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsHeadlinesSEC FilingsShort InterestTrendsBuy This Stock BDRX vs. PLRX, ANIX, ONCY, ZNTL, SRZN, VIRI, SCLX, TCRX, ADAG, and QNCXShould you be buying Biodexa Pharmaceuticals stock or one of its competitors? The main competitors of Biodexa Pharmaceuticals include Pliant Therapeutics (PLRX), Anixa Biosciences (ANIX), Oncolytics Biotech (ONCY), Zentalis Pharmaceuticals (ZNTL), Surrozen (SRZN), Virios Therapeutics (VIRI), Scilex (SCLX), TScan Therapeutics (TCRX), Adagene (ADAG), and Quince Therapeutics (QNCX). These companies are all part of the "pharmaceutical products" industry. Biodexa Pharmaceuticals vs. Its Competitors Pliant Therapeutics Anixa Biosciences Oncolytics Biotech Zentalis Pharmaceuticals Surrozen Virios Therapeutics Scilex TScan Therapeutics Adagene Quince Therapeutics Pliant Therapeutics (NASDAQ:PLRX) and Biodexa Pharmaceuticals (NASDAQ:BDRX) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, institutional ownership, risk, dividends, earnings, profitability, media sentiment and analyst recommendations. Does the media favor PLRX or BDRX? In the previous week, Pliant Therapeutics had 5 more articles in the media than Biodexa Pharmaceuticals. MarketBeat recorded 7 mentions for Pliant Therapeutics and 2 mentions for Biodexa Pharmaceuticals. Biodexa Pharmaceuticals' average media sentiment score of 0.32 beat Pliant Therapeutics' score of -0.15 indicating that Biodexa Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Pliant Therapeutics 2 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Biodexa Pharmaceuticals 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Which has preferable valuation and earnings, PLRX or BDRX? Biodexa Pharmaceuticals has lower revenue, but higher earnings than Pliant Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioPliant Therapeutics$1.58M64.50-$210.30M-$3.61-0.46Biodexa Pharmaceuticals$470K55.37-$7.32MN/AN/A Do analysts rate PLRX or BDRX? Pliant Therapeutics currently has a consensus price target of $8.19, indicating a potential upside of 393.22%. Given Pliant Therapeutics' stronger consensus rating and higher possible upside, equities analysts clearly believe Pliant Therapeutics is more favorable than Biodexa Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Pliant Therapeutics 0 Sell rating(s) 12 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.08Biodexa Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Is PLRX or BDRX more profitable? Biodexa Pharmaceuticals' return on equity of 0.00% beat Pliant Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Pliant TherapeuticsN/A -68.45% -52.29% Biodexa Pharmaceuticals N/A N/A N/A Do insiders and institutionals have more ownership in PLRX or BDRX? 97.3% of Pliant Therapeutics shares are owned by institutional investors. Comparatively, 17.5% of Biodexa Pharmaceuticals shares are owned by institutional investors. 8.0% of Pliant Therapeutics shares are owned by company insiders. Comparatively, 0.3% of Biodexa Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth. Which has more risk and volatility, PLRX or BDRX? Pliant Therapeutics has a beta of 1.42, indicating that its share price is 42% more volatile than the S&P 500. Comparatively, Biodexa Pharmaceuticals has a beta of 0.98, indicating that its share price is 2% less volatile than the S&P 500. SummaryPliant Therapeutics beats Biodexa Pharmaceuticals on 9 of the 13 factors compared between the two stocks. Get Biodexa Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for BDRX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding BDRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart BDRX vs. The Competition Export to ExcelMetricBiodexa PharmaceuticalsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$26.06M$2.99B$5.52B$9.72BDividend YieldN/A2.42%4.60%4.12%P/E RatioN/A17.2130.0124.75Price / Sales55.37310.81450.0597.82Price / CashN/A41.7736.7758.47Price / Book2.457.318.185.59Net Income-$7.32M-$54.43M$3.26B$265.99M7 Day Performance6.42%0.01%6.13%5.06%1 Month Performance-19.84%0.63%0.07%0.61%1 Year PerformanceN/A8.41%36.31%22.82% Biodexa Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)BDRXBiodexa Pharmaceuticals0.1571 of 5 stars$7.13+4.9%N/AN/A$26.06M$470K0.0020Short Interest ↑Gap UpPLRXPliant Therapeutics3.8578 of 5 stars$1.70+7.6%$13.31+683.1%-86.5%$96.99M$1.58M-0.4790News CoverageEarnings ReportAnalyst ForecastGap DownANIXAnixa Biosciences3.4625 of 5 stars$3.26+8.3%$9.00+176.1%-5.1%$96.96M$210K-8.585Analyst ForecastONCYOncolytics Biotech2.2802 of 5 stars$0.88-10.8%$4.33+390.7%-12.4%$96.43MN/A-3.0530News CoverageEarnings ReportGap UpZNTLZentalis Pharmaceuticals2.4769 of 5 stars$1.39+3.7%$8.37+501.9%-52.0%$96.42M$67.43M-0.44160News CoverageEarnings ReportAnalyst ForecastAnalyst RevisionSRZNSurrozen2.7624 of 5 stars$10.71-2.7%$38.50+259.6%+33.7%$94.19M$10.65M-0.4380News CoverageEarnings ReportUpcoming EarningsVIRIVirios Therapeutics0.1103 of 5 stars$4.85+0.3%$5.00+3.1%+2,702.3%$93.40MN/A-17.965News CoverageSCLXScilex2.0608 of 5 stars$14.96+11.6%$455.00+2,941.4%-64.6%$93.22M$50.71M-0.5280Upcoming EarningsGap DownTCRXTScan Therapeutics3.6935 of 5 stars$1.71+5.6%$7.80+356.1%-72.3%$91.68M$2.82M-1.57100Positive NewsUpcoming EarningsADAGAdagene2.772 of 5 stars$1.95+1.5%$8.00+310.5%-10.3%$90.45M$100K0.00260News CoverageAnalyst ForecastAnalyst RevisionQNCXQuince Therapeutics3.0177 of 5 stars$1.63-3.0%$8.00+390.8%+139.1%$90.09MN/A-1.1760Upcoming EarningsAnalyst ForecastShort Interest ↑ Related Companies and Tools Related Companies Pliant Therapeutics Competitors Anixa Biosciences Competitors Oncolytics Biotech Competitors Zentalis Pharmaceuticals Competitors Surrozen Competitors Virios Therapeutics Competitors Scilex Competitors TScan Therapeutics Competitors Adagene Competitors Quince Therapeutics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:BDRX) was last updated on 8/10/2025 by MarketBeat.com Staff From Our PartnersGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredGreen Light for These StocksGuess Who Washington Will Partner With Next? The U.S. government just made a bold $400 million move... beco...Stansberry Research | SponsoredAltucher: $900 to $108,000? Trump’s “Great Gain” Is HereJames Altucher says two recent events could trigger a historic wealth shift—one driven by a radical Trump poli...Paradigm Press | Sponsored"Death Spiral" Threatening Your SavingsThe "Death Spiral" Threatening Your Savings But this time, it's not just Dalio ringing the alarm bells…Goldco Precious Metals | SponsoredTake a look at this picture ...A strange investment secret — discovered just a few short weeks before this image was taken — correctly predic...Weiss Ratings | SponsoredNational 'Stock Market Reset' Coming September 30 (New WH Order)Crash Coming Sept 30? Analysts Warn of New Crisis A new problem on the U.S. power grid is putting millions ...Altimetry | SponsoredFed Decision Warning: How to Protect Your Wealth Before September 17th On September 17th, the Fed faces an impossible choice—and Wall Street insiders are already preparing for the...American Alternative | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Biodexa Pharmaceuticals PLC Unsponsored ADR Please log in to your account or sign up in order to add this asset to your watchlist. Share Biodexa Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
